To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
As aging is associated with decreased estradiol production in women, so is aging associated with decreased testosterone production in men. In this chapter, Pike and Rosario review novel and compelling data indicating testosterone regulation of β-amyloid production in the brain, as well as significant associations between low testosterone levels and risk for Alzheimer's-related dementia in men. Based on these data and on the various mechanisms by which testosterone can exert neuroprotective effects in brain, the authors conclude that low testosterone is a likely risk factor for Alzheimer's-related dementia in men. Their analysis points out the need for research focusing on the development of brain-selective androgen receptor modulators (SARMs) for use in the prevention of Alzheimer's disease (AD) in men.
Estrogen-based therapies often include a progestin to antagonize tumorigenic effects of estrogens in the uterus. While much has been learned about the functional and neuroprotective effects of estrogens in the brain, far less is known about the effects of progestins, particularly specific progestins like progesterone and medroxy-progesterone acetate, used either alone or in combination with estrogenic therapies. In this chapter, Pike and Carroll review many of the effects on cell survival and function, first of estrogens, and then of progestins. While not all progestins are alike, the authors find that prolonged exposure to progestins often will decrease the protective effects of estradiol on cell survival and function. Evidence suggests that a cyclical regimen of estradiol and progesterone may be most efficacious. Ultimately, the development of neural selective estrogen receptor modulators (SERMs) with the potential to circumvent the need for, and hence the negative neural consequences of, progesterone will be an important advance to estrogen-based therapies.
Email your librarian or administrator to recommend adding this to your organisation's collection.